Deborah Hagan
Janssen (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Metabolism, Diabetes, and Cancer, Amino Acid Enzymes and Metabolism, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes(2008)617 cited
- → Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats(2008)417 cited
- → Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members(2010)301 cited
- → Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: A sequestration mechanism in metabolic regulation(1999)153 cited
- → Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators.(1994)125 cited
- → Expression of Human Hepatic Glucokinase in Transgenic Mice Liver Results in Decreased Glucose Levels and Reduced Body Weight(1997)101 cited
- → Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2(2008)57 cited
- → Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor(2013)38 cited
- → Identification of small-molecule protein–protein interaction inhibitors for NKG2D(2023)11 cited